Skip to content

Study · Observational study · n = 141 · 2026

9 results

Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus.

Qaisar R, Khan IU, Rehman AU, Iqbal MS, Ahmad F, Karim A

British journal of clinical pharmacology25 Aug 2025Cited by 4 (Europe PMC)

PMID40855709 (opens in a new tab)DOI10.1002/bcp.70253 (opens in a new tab)PepBankPUB-40855709
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studySafety outcome

    In older men with type 2 diabetes, plasma CAF22 rose more with semaglutide than with sitagliptin (P < .05).

    In plain wordsIn older men with type 2 diabetes, a blood marker of neuromuscular junction damage rose more on semaglutide than on sitagliptin.

    Peptide
    Semaglutide
    Outcome
    IncreasePlasma C-terminal agrin fragment 22 (CAF22)
    Study

    n = 141

    Comparator
    Sitagliptin
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Concurrently, this group exhibited more pronounced elevation of plasma CAF22 and NfL levels compared to the sitagliptin group (all P < .05).
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.
  2. 02HumanObservational studySafety outcome

    In older men with type 2 diabetes, plasma NfL rose more with semaglutide than with sitagliptin (P < .05).

    In plain wordsIn older men with type 2 diabetes, a blood marker of nerve damage rose more on semaglutide than on sitagliptin.

    Peptide
    Semaglutide
    Outcome
    IncreasePlasma neurofilament light chain (NfL)
    Study

    n = 141

    Comparator
    Sitagliptin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Concurrently, this group exhibited more pronounced elevation of plasma CAF22 and NfL levels compared to the sitagliptin group (all P < .05).
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.
  3. 03HumanObservational studySafety outcome

    In older men with type 2 diabetes, handgrip strength fell over 1 year in the semaglutide group (P < .05).

    In plain wordsIn older men with type 2 diabetes, handgrip strength was lower after 1 year on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHandgrip strength
    Study

    n = 68

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Over the study period, the semaglutide group exhibited significant reductions in HGS, gait speed, ASMI and SPPB scores (all P < .05).
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.
  4. 04HumanObservational studySafety outcome

    In older men with type 2 diabetes, gait speed fell over 1 year in the semaglutide group (P < .05).

    In plain wordsIn older men with type 2 diabetes, walking speed was lower after 1 year on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseGait speed
    Study

    n = 68

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Over the study period, the semaglutide group exhibited significant reductions in HGS, gait speed, ASMI and SPPB scores (all P < .05).
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.
  5. 05HumanObservational studySafety outcome

    In older men with type 2 diabetes, appendicular skeletal muscle mass index fell over 1 year in the semaglutide group (P < .05).

    In plain wordsIn older men with type 2 diabetes, muscle mass index was lower after 1 year on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseAppendicular skeletal muscle mass index (ASMI)
    Study

    n = 68

    Comparator
    Baseline
    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Over the study period, the semaglutide group exhibited significant reductions in HGS, gait speed, ASMI and SPPB scores (all P < .05).
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.
  6. 06HumanObservational studySafety outcome

    In older men with type 2 diabetes, short physical performance battery scores fell over 1 year in the semaglutide group (P < .05).

    In plain wordsIn older men with type 2 diabetes, physical performance scores were lower after 1 year on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseShort physical performance battery (SPPB) score
    Study

    n = 68

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Over the study period, the semaglutide group exhibited significant reductions in HGS, gait speed, ASMI and SPPB scores (all P < .05).
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.
  7. 07HumanObservational studyOther

    Among older men with type 2 diabetes taking semaglutide, higher CAF22 and NfL levels generally correlated with poorer handgrip strength, ASMI and SPPB scores.

    In plain wordsAmong older men with type 2 diabetes on semaglutide, higher levels of two damage markers were linked to weaker muscle and physical performance.

    Peptide
    Semaglutide
    Outcome
    Not applicableAssociation of CAF22 and NfL with HGS, ASMI and SPPB
    Study

    n = 68

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Among the patients taking semaglutide, higher CAF22 and NfL levels generally correlated with poorer HGS, ASMI and SPPB scores.
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.
  8. 08HumanObservational studyOther

    Among older men with type 2 diabetes taking semaglutide, lower BDNF levels were associated with reduced ASMI and SPPB at specific time points (P < .05).

    In plain wordsAmong older men with type 2 diabetes on semaglutide, lower BDNF levels were linked to lower muscle mass index and performance at some time points.

    Peptide
    Semaglutide
    Outcome
    Not applicableAssociation of BDNF with ASMI and SPPB
    Study

    n = 68

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    In contrast, lower BDNF levels were associated with reduced ASMI and SPPB at specific time points (all P < .05).
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.
  9. 09HumanObservational studyOther

    In multiple regression among patients taking semaglutide, CAF22 and NfL were negatively associated, and BDNF positively associated, with sarcopenia parameters.

    In plain wordsAmong people taking semaglutide, higher CAF22 and NfL were linked to worse sarcopenia measures, and higher BDNF to better ones.

    Peptide
    Semaglutide
    Outcome
    Not applicableRegression of sarcopenia parameters on CAF22, NfL and BDNF
    Study

    n = 68

    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Multiple regression analysis confirmed significant negative associations between CAF22 and NfL, and a positive association between BDNF and sarcopenia parameters, specifically among patients taking semaglutide.
    1 context sentence
    Summary · context
    A cohort of 141 older men with T2DM (semaglutide, n = 68; sitagliptin group, n = 73) underwent assessments at baseline, 6 months and 1 year.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.